J. Corley

ForSight VISION5, Inc. develops ocular drug delivery technologies and device solutions for ophthalmic diseases. It engages in the development of non-invasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. Its lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The company was founded by Eugene de Juan Jr., J. Andrew Corley and K. Angela Macfarlane in 2010 and is headquartered in Madison, NJ.

Equinox Ophthalmic, Inc. operates as a biotechnology company. It specializes in cataract, corneal and glaucoma surgery. The company was founded by John Berdahl and is headquartered in Sioux Falls, SD.

Iantrek Inc provides biotechnology services. The company is headquartered in White Plains, NY.

Neurolens, Inc. is a company that commercializes breakthrough technology to improve vision care. The company's patented contoured prism technology provides visual comfort for the nearly 65% of US adults who complain of headaches, neck/shoulder pain, and eyestrain when using digital devices, reading, or doing detail work. The company is based in Coppell, TX. Inspired by a breakthrough discovery linking optometry and neurology, Neurolens is unlocking a new dimension of vision care. The Neurolens contoured prism design helps the eyes work together comfortably, bringing the eyes into alignment to relieve painful symptoms. The technology is only available to independent eye care providers. The company was founded in 2012 by Davis Corley, and Pierre Bertrand has been the CEO of the company since 2019.

Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY.

Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA.

Melt Pharmaceuticals, Inc. engages in the development and commercialization of proprietary non-opioid, non-intravenous, or non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. It intends to seek regulatory approval through the FDA regulatory pathway for the proprietary, patented small-molecule product candidates. The company was founded by Mark L. Baum on April 3, 2018 and is headquartered in Brentwood, TN.

BELKIN Vision Ltd. provides glaucoma laser treatment. The company was founded by Michael Belkin in 2013 and is headquartered in Tel Aviv, Israel.

ReVision Optics, Inc. develops optical solutions for the treatment of presbyopia. The company also develops Raindrop Near Vision Corneal Inlay, which is a refractive surgery solution. ReVision Optics was founded by Hansen A. Yuan, Adrian Koppes and Alok Nigam in 1996 and is headquartered Lake Forest, CA.

Flying L Management LLC (Flying L Management) is a venture capital firm founded in 2016. The firm is headquartered in Newport beach, California.